Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
ACHC vs UNH vs CVS vs UHS vs OSCR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Care Facilities
Medical - Healthcare Plans
ACHC vs UNH vs CVS vs UHS vs OSCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Care Facilities | Medical - Healthcare Plans |
| Market Cap | $2.25B | $335.60B | $111.40B | $10.68B | $5.41B |
| Revenue (TTM) | $3.37B | $449.71B | $407.90B | $17.76B | $13.30B |
| Net Income (TTM) | $-1.11B | $12.04B | $2.93B | $1.52B | $-39M |
| Gross Margin | 56.2% | 18.8% | 13.9% | 67.6% | 17.4% |
| Operating Margin | 11.7% | 4.2% | 1.5% | 11.5% | 0.1% |
| Forward P/E | 16.4x | 20.2x | 12.2x | 7.3x | 34.7x |
| Total Debt | $2.65B | $78.39B | $93.59B | $5.51B | $430M |
| Cash & Equiv. | $133M | $24.36B | $8.51B | $138M | $2.77B |
ACHC vs UNH vs CVS vs UHS vs OSCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Acadia Healthcare C… (ACHC) | 100 | 42.8 | -57.2% |
| UnitedHealth Group … (UNH) | 100 | 99.4 | -0.6% |
| CVS Health Corporat… (CVS) | 100 | 116.1 | +16.1% |
| Universal Health Se… (UHS) | 100 | 127.9 | +27.9% |
| Oscar Health, Inc. (OSCR) | 100 | 77.6 | -22.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACHC vs UNH vs CVS vs UHS vs OSCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ACHC lags the leaders in this set but could rank higher in a more targeted comparison.
UNH is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 25 yrs, beta 0.59, yield 2.4%
- Rev growth 11.8%, EPS growth -14.7%, 3Y rev CAGR 11.4%
- 220.6% 10Y total return vs UHS's 30.8%
CVS carries the broadest edge in this set and is the clearest fit for defensive.
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Beta 0.05 vs OSCR's 1.84
- 3.1% yield, vs UNH's 2.4%, (2 stocks pay no dividend)
- +34.7% vs UHS's -8.2%
UHS is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.
- Lower volatility, beta 0.60, Low D/E 74.3%, current ratio 1.05x
- Lower P/E (7.3x vs 20.2x)
- 8.6% margin vs ACHC's -32.8%
- 9.8% ROA vs ACHC's -18.6%, ROIC 12.3% vs 5.9%
OSCR ranks third and is worth considering specifically for growth.
- 27.5% revenue growth vs ACHC's 5.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.5% revenue growth vs ACHC's 5.0% | |
| Value | Lower P/E (7.3x vs 20.2x) | |
| Quality / Margins | 8.6% margin vs ACHC's -32.8% | |
| Stability / Safety | Beta 0.05 vs OSCR's 1.84 | |
| Dividends | 3.1% yield, vs UNH's 2.4%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +34.7% vs UHS's -8.2% | |
| Efficiency (ROA) | 9.8% ROA vs ACHC's -18.6%, ROIC 12.3% vs 5.9% |
ACHC vs UNH vs CVS vs UHS vs OSCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ACHC vs UNH vs CVS vs UHS vs OSCR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
OSCR leads in 1 of 6 categories
UHS leads 1 • CVS leads 1 • ACHC leads 0 • UNH leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
OSCR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 133.4x ACHC's $3.4B. UHS is the more profitable business, keeping 8.6% of every revenue dollar as net income compared to ACHC's -32.8%. On growth, OSCR holds the edge at +52.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3.4B | $449.7B | $407.9B | $17.8B | $13.3B |
| EBITDAEarnings before interest/tax | $588M | $23.2B | $10.5B | $2.7B | $40M |
| Net IncomeAfter-tax profit | -$1.1B | $12.0B | $2.9B | $1.5B | -$39M |
| Free Cash FlowCash after capex | -$215M | $19.7B | $7.4B | $894M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +56.2% | +18.8% | +13.9% | +67.6% | +17.4% |
| Operating MarginEBIT ÷ Revenue | +11.7% | +4.2% | +1.5% | +11.5% | +0.1% |
| Net MarginNet income ÷ Revenue | -32.8% | +2.7% | +0.7% | +8.6% | -0.3% |
| FCF MarginFCF ÷ Revenue | -6.4% | +4.4% | +1.8% | +5.0% | +21.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.6% | +2.0% | +6.2% | +9.6% | +52.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -49.8% | +0.7% | +63.1% | +17.7% | +125.0% |
Valuation Metrics
Evenly matched — UHS and OSCR each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 7.4x trailing earnings, UHS trades at a 88% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, UHS's 6.1x EV/EBITDA is more attractive than UNH's 16.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.3B | $335.6B | $111.4B | $10.7B | $5.4B |
| Enterprise ValueMkt cap + debt − cash | $4.8B | $389.6B | $196.5B | $16.0B | $3.1B |
| Trailing P/EPrice ÷ TTM EPS | -2.01x | 27.95x | 62.81x | 7.38x | -12.35x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.42x | 20.19x | 12.19x | 7.30x | 34.65x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.46x | — |
| EV / EBITDAEnterprise value multiple | 8.27x | 16.70x | 13.11x | 6.14x | — |
| Price / SalesMarket cap ÷ Revenue | 0.68x | 0.75x | 0.28x | 0.61x | 0.46x |
| Price / BookPrice ÷ Book value/share | 1.04x | 3.31x | 1.47x | 1.48x | 5.58x |
| Price / FCFMarket cap ÷ FCF | — | 20.88x | 14.27x | 12.57x | 5.11x |
Profitability & Efficiency
UHS leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
UHS delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-41 for ACHC. OSCR carries lower financial leverage with a 0.44x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs OSCR's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -40.9% | +11.5% | +3.9% | +20.7% | -3.3% |
| ROA (TTM)Return on assets | -18.6% | +3.9% | +1.1% | +9.8% | -0.6% |
| ROICReturn on invested capital | +5.9% | +9.2% | +5.0% | +12.3% | — |
| ROCEReturn on capital employed | +7.5% | +9.7% | +6.1% | +16.0% | -25.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 6 | 4 |
| Debt / EquityFinancial leverage | 1.24x | 0.77x | 1.24x | 0.74x | 0.44x |
| Net DebtTotal debt minus cash | $2.5B | $54.0B | $85.1B | $5.4B | -$2.3B |
| Cash & Equiv.Liquid assets | $133M | $24.4B | $8.5B | $138M | $2.8B |
| Total DebtShort + long-term debt | $2.7B | $78.4B | $93.6B | $5.5B | $430M |
| Interest CoverageEBIT ÷ Interest expense | -5.99x | 4.71x | 2.11x | 10.92x | -0.57x |
Total Returns (Dividends Reinvested)
Evenly matched — CVS and OSCR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVS five years ago would be worth $11,700 today (with dividends reinvested), compared to $3,823 for ACHC. Over the past 12 months, CVS leads with a +34.7% total return vs UHS's -8.2%. The 3-year compound annual growth rate (CAGR) favors OSCR at 40.5% vs ACHC's -29.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +71.2% | +10.6% | +10.6% | -22.3% | +39.4% |
| 1-Year ReturnPast 12 months | +1.2% | -3.2% | +34.7% | -8.2% | +22.6% |
| 3-Year ReturnCumulative with dividends | -64.5% | -19.9% | +36.6% | +20.8% | +177.5% |
| 5-Year ReturnCumulative with dividends | -61.8% | -2.6% | +17.0% | +12.5% | -7.3% |
| 10-Year ReturnCumulative with dividends | -58.5% | +220.6% | +3.5% | +30.8% | -40.0% |
| CAGR (3Y)Annualised 3-year return | -29.2% | -7.1% | +11.0% | +6.5% | +40.5% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than OSCR's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs UHS's 69.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.84x | 0.59x | 0.05x | 0.60x | 1.84x |
| 52-Week HighHighest price in past year | $30.20 | $395.52 | $88.63 | $246.33 | $23.80 |
| 52-Week LowLowest price in past year | $11.43 | $234.60 | $58.35 | $152.33 | $10.69 |
| % of 52W HighCurrent price vs 52-week peak | +81.0% | +93.5% | +98.5% | +69.2% | +87.7% |
| RSI (14)Momentum oscillator 0–100 | 46.2 | 75.9 | 69.3 | 39.7 | 78.5 |
| Avg Volume (50D)Average daily shares traded | 3.1M | 7.9M | 7.4M | 793K | 6.5M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ACHC as "Buy", UNH as "Buy", CVS as "Buy", UHS as "Hold", OSCR as "Hold". Consensus price targets imply 35.7% upside for UHS (target: $232) vs -19.7% for OSCR (target: $17). For income investors, CVS offers the higher dividend yield at 3.06% vs UHS's 0.47%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $23.50 | $385.43 | $95.20 | $231.50 | $16.75 |
| # AnalystsCovering analysts | 25 | 52 | 41 | 43 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | +2.4% | +3.1% | +0.5% | — |
| Dividend StreakConsecutive years of raises | 1 | 25 | 0 | 1 | — |
| Dividend / ShareAnnual DPS | — | $8.70 | $2.67 | $0.80 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.2% | +1.7% | 0.0% | +9.1% | 0.0% |
OSCR leads in 1 of 6 categories (Income & Cash Flow). UHS leads in 1 (Profitability & Efficiency). 3 tied.
ACHC vs UNH vs CVS vs UHS vs OSCR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ACHC or UNH or CVS or UHS or OSCR a better buy right now?
For growth investors, Oscar Health, Inc.
(OSCR) is the stronger pick with 27. 5% revenue growth year-over-year, versus 5. 0% for Acadia Healthcare Company, Inc. (ACHC). Universal Health Services, Inc. (UHS) offers the better valuation at 7. 4x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Acadia Healthcare Company, Inc. (ACHC) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ACHC or UNH or CVS or UHS or OSCR?
On trailing P/E, Universal Health Services, Inc.
(UHS) is the cheapest at 7. 4x versus CVS Health Corporation at 62. 8x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x.
03Which is the better long-term investment — ACHC or UNH or CVS or UHS or OSCR?
Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.
0%, compared to -61. 8% for Acadia Healthcare Company, Inc. (ACHC). Over 10 years, the gap is even starker: UNH returned +220. 6% versus ACHC's -58. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ACHC or UNH or CVS or UHS or OSCR?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately 3531% more volatile than CVS relative to the S&P 500. On balance sheet safety, Oscar Health, Inc. (OSCR) carries a lower debt/equity ratio of 44% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — ACHC or UNH or CVS or UHS or OSCR?
By revenue growth (latest reported year), Oscar Health, Inc.
(OSCR) is pulling ahead at 27. 5% versus 5. 0% for Acadia Healthcare Company, Inc. (ACHC). On earnings-per-share growth, the picture is similar: Universal Health Services, Inc. grew EPS 37. 3% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ACHC or UNH or CVS or UHS or OSCR?
Universal Health Services, Inc.
(UHS) is the more profitable company, earning 8. 6% net margin versus -33. 3% for Acadia Healthcare Company, Inc. — meaning it keeps 8. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACHC leads at 11. 7% versus -3. 4% for OSCR. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ACHC or UNH or CVS or UHS or OSCR more undervalued right now?
On forward earnings alone, Universal Health Services, Inc.
(UHS) trades at 7. 3x forward P/E versus 34. 7x for Oscar Health, Inc. — 27. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for UHS: 35. 7% to $231. 50.
08Which pays a better dividend — ACHC or UNH or CVS or UHS or OSCR?
In this comparison, CVS (3.
1% yield), UNH (2. 4% yield), UHS (0. 5% yield) pay a dividend. ACHC, OSCR do not pay a meaningful dividend and should not be held primarily for income.
09Is ACHC or UNH or CVS or UHS or OSCR better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, OSCR: -40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ACHC and UNH and CVS and UHS and OSCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ACHC is a small-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; UHS is a mid-cap deep-value stock; OSCR is a small-cap high-growth stock. UNH, CVS pay a dividend while ACHC, UHS, OSCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.